Menopause — NZ Condition Guide | KiwiMeds

What is Menopause?

Menopause is the natural end of menstrual periods, occurring when the ovaries stop producing eggs and oestrogen levels fall. It is confirmed after 12 consecutive months without a period. The average age of menopause in NZ is 51–52. Perimenopause — the transition phase with hormonal fluctuations and symptoms — can begin several years before menopause.

Overview

Menopausal symptoms vary widely in severity. Common symptoms include hot flushes (sudden feelings of heat spreading through the body and face), night sweats, sleep disturbance, mood changes (irritability, anxiety, low mood), brain fog, vaginal dryness and discomfort, reduced libido, joint aches, and changes in skin and hair. Symptoms typically last 4–7 years but can continue much longer. Menopause also increases the long-term risk of osteoporosis and cardiovascular disease.

Treatment in New Zealand

Hormone replacement therapy (HRT) — also called menopause hormone therapy (MHT) — is the most effective treatment for hot flushes, night sweats, and vaginal symptoms, and also protects against osteoporosis. Modern HRT (using body-identical oestrogen and progesterone) is generally safe for most women. Pharmac funds several HRT preparations. For women who cannot or prefer not to take HRT, other options include SSRIs (paroxetine, venlafaxine), gabapentin, and clonidine. Vaginal oestrogen (for dryness/discomfort) is safe for most women.

NZ-Specific Information

The Australasian Menopause Society (menopause.org.au) provides evidence-based information. Pharmac funds several HRT preparations. GPs in NZ are increasingly up-to-date with modern HRT guidance — if your GP is not comfortable prescribing HRT, you can ask for a referral to a GP with a special interest or a gynaecologist.

Frequently Asked Questions

Does HRT cause breast cancer? The HRT-breast cancer risk has been significantly overstated. Modern body-identical HRT (oestrogen + micronised progesterone) has minimal breast cancer risk, similar to alcohol or obesity. The benefits for most women outweigh risks. Discuss your personal risk with your GP. How long can I take HRT? For most women, there is no mandatory time limit. Duration should be based on individual benefits and risks, reviewed regularly.

Supplements That May Support Management

⚠️ Important: The supplements listed below have varying levels of clinical evidence. They are not a substitute for prescribed medications and should only be considered as adjunctive support under the guidance of a qualified healthcare professional. Always inform your GP or pharmacist before commencing any supplement, as interactions with prescribed medicines are possible.

• Calcium and Vitamin D — The accelerated bone loss in the peri- and post-menopausal period due to oestrogen decline makes adequate calcium and vitamin D intake critical for osteoporosis prevention. Supplementation is recommended where dietary intake is insufficient. Target: 1200 mg calcium/day and 800–2000 IU vitamin D/day.
• Isoflavones (Red Clover or Soy Isoflavones) — Phytoestrogens from red clover (biochanin A, formononetin) and soy (genistein, daidzein) bind oestrogen receptors and may modestly reduce vasomotor symptoms (hot flushes) in clinical trials. Effect is modest (20–40% reduction) but meaningful for those preferring non-hormonal approaches. Discuss with your doctor if you have oestrogen-sensitive conditions.
• Black Cohosh — Black cohosh (Actaea racemosa) has evidence supporting modest reductions in hot flush frequency and severity. It does not appear to act directly on oestrogen receptors. A 2–3 month trial is needed before assessing benefit. Use should be medically supervised due to rare hepatotoxicity reports.
• Magnesium — Magnesium deficiency is common in peri-menopause and supplementation may reduce mood disturbance, sleep disruption, and hot flush severity.
• Omega-3 Fatty Acids — Omega-3 supplementation has demonstrated reductions in hot flush frequency and depressive symptom severity in peri-menopausal women.

Relevant Vaccinations

Individuals living with menopause may benefit from the following vaccinations. Please discuss your vaccination status with your GP or practice nurse, as eligibility and funding through the New Zealand National Immunisation Schedule may apply.

• Influenza (annual) — Funded for women aged 65 and over. Recommended as part of comprehensive preventive health in peri- and post-menopausal women.
• Shingles (Shingrix) — Recommended from age 50. Post-menopausal women are in the highest-risk age group for herpes zoster. Shingrix provides >90% protection against shingles and post-herpetic neuralgia.
• Pneumococcal — Recommended from age 65, or earlier if other health conditions are present.
• COVID-19 — Maintaining up-to-date COVID-19 vaccination is recommended, particularly for those with menopausal metabolic changes increasing cardiovascular risk.

Dietary Guidance

Evidence-based dietary modifications play a meaningful role in the management of menopause. The following foods are generally recommended as part of a balanced, condition-appropriate diet. A referral to a registered dietitian may be beneficial for personalised nutritional planning.

• Phytoestrogen-rich foods (soy, flaxseed, tofu, tempeh) — Dietary phytoestrogens can modestly reduce hot flush frequency and support hormonal transition. Soy consumption of 1–2 servings/day has evidence from Japanese women studies with low hot flush rates.
• Calcium-rich foods (dairy, fortified plant milks, sardines with bones) — Essential for protecting bone mineral density during the accelerated post-menopausal bone loss phase.
• Oily fish and flaxseed (omega-3 sources) — Supports cardiovascular health and may reduce vasomotor symptom severity.
• Colourful fruits and vegetables — Rich in antioxidants and phytoestrogens. Mediterranean dietary adherence in menopause is associated with reduced symptom burden and cardiovascular risk.
• Limit: alcohol, caffeine, spicy foods, hot drinks — These are well-recognised hot flush triggers. Reducing caffeine and alcohol intake (particularly in the evening) may meaningfully reduce vasomotor symptom frequency and severity.

Related Conditions & Medications

Related medications: Levothyroxine. Related conditions: Osteoporosis, Anxiety.